Synaffix BV
Diana Čekatauskaitė has an extensive background in business development, investment analysis, and life sciences management consulting. Diana currently holds the position of Associate Director, Business Development at Synaffix BV, a company that focuses on targeted cancer therapeutics. Diana previously worked at M Ventures and Arthur D. Little in business development and investment analysis roles. Diana also has experience in research as a Research Assistant at Karolinska Institutet and with the Molly Stevens group at Imperial College London. Diana holds a Master's degree in Medical Science with a Major in Bioentrepreneurship from Karolinska Institutet.
Synaffix BV
Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy). Our platform is commercially validated by well over $7.6 billion in technology out-licensing deals with partners including ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin. These partnerships have rapidly translated Synaffix technology into >20 ADCs currently in development by our partners, where 5 of these have already initiated Phase 1 clinical trials. Through the platform, we can rapidly generate best-in-class ADCs for our partners from any antibody and our patent portfolio protects our proprietary processes and any resulting Products through at least 2039. Additionally, Synaffix technology is being deployed to address unmet medical need in several multi-billion-dollar, high growth market segments such as immune cell engagers and targeted gene therapy. Synaffix BV was acquired by Lonza in May 2023.